Ekso Bionics acquires Parker Hannifin's HMC business for $10M; HMC had $2.2M op loss in FY2022

EKSO BIONICS HOLDINGS, INC.

Acquisition closed Dec 5, 2022; purchase price $10M: $5M cash + $5M subordinated zero-coupon note due Sep 2027.
HMC FY2022 (Jun 2022) revenue $4.3M, operating loss $2.2M; FY2021 loss $4.0M on $2.7M revenue.
Pro forma 9mo Sep 2022 combined net loss $14.8M ($1.14 diluted EPS) vs Ekso standalone $11.9M loss.
Preliminary purchase price allocation: $5.2M intangible assets, $0.7M goodwill, $1.0M property step-ups.
HMC unaudited 3mo Sep 2022 revenue $390k, operating loss $1.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.